Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for AFINITOR
- Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
- Study of Ribociclib and Everolimus in HGG and DIPG
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
- Adjunctive Everolimus Treatment of Refractory Epilepsy
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults
- Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)
- Cemiplimab in AlloSCT/SOT Recipients With CSCC
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
- A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Itacitinib + Everolimus in Hodgkin Lymphoma
- Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
- Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
- Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
- A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
- Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
- A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)
- ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With Renal Cell Carcinoma (RCC)
- Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
- Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
- A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
- RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome
- Circulating Tumor Cells and Tumor DNA in HCC and NET
- Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
- Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
- Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients
- Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
- Safety and Durability of Sirolimus for Treatment of LAM
- Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
- Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
- Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
- Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
- Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
- Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
- Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
- Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
- Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
- Phase II Study of Everolimus Beyond Progression
- Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET)
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
- Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
- A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
- An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis
- Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
- Everolimus for Children With Recurrent or Progressive Ependymoma
- Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
- LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
- S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer
- Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
- Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- Safety of Simvastatin in LAM and TSC
- Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
- Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
- DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
- Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
- Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women
- Everolimus With and Without Temozolomide in Adult Low Grade Glioma
- A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas
- Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
- Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
- NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
- Rapalogues for Autism Phenotype in TSC: A Feasibility Study
- Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
- A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
- Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
- MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
- Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
- Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma
- The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium
- A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
- Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
- A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
- Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
- Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
- Sequential Therapy in Metastatic Renal Cell Carinoma
- Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
- Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
- Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
- Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
- Everolimus in Treating Cutaneous T-cell Lymphoma
- Exemestane-RAD001-Metformin
- Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
- Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
- An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Adv
- Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
- Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
- Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
- Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
- Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
- Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
- Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
- A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
- Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
- Everolimus in Refractory Testicular Germ Cell Cancer
- BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
- Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
- Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
- Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
- Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study
- Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
- Rotating Pazopanib and Everolimus to Avoid Resistance
- Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
- GSK1120212 Rollover Study
- Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
- Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
- RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
- Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
- Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
- Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
- A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
- Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
- Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
- Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
- Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
- Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
- Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
- Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
- Study of Everolimus (RAD001) in Combination With Lenalidomide
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
- A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
- Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
- Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
- Everolimus and LongActing Octreotide Trial in Polycystic Livers
- Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
- A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
- RAD001 Plus Carboplatin in Breast Cancer Patients
- Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer
- Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
- Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or
- Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
- Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
- Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
- RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
- RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
- Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors
- Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
- Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
- Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
- RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
- Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
- Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
- Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
- Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
- Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
- Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
- Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
- Everolimus in Treating Patients With Recurrent Low-Grade Glioma
- Everolimus in Treating Patients With Recurrent Low-Grade Glioma
- Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
- Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
- Treatment of Patients With RAD001 With Progressive Sarcoma
- Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
- Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
- Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
- Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
- RAD001 Plus Bevacizumab in Metastatic Melanoma
- Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy
- Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
- RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
Clinical trials list
click for details